Validation of the short Mood and Feelings Questionnaire in young adulthood.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 11 2021
Historique:
received: 22 01 2021
revised: 30 04 2021
accepted: 11 07 2021
pubmed: 11 8 2021
medline: 30 10 2021
entrez: 10 8 2021
Statut: ppublish

Résumé

Depression often onsets in adolescence and is associated with recurrence in adulthood. There is a need to identify and monitor depression symptoms across adolescence and into young adulthood. The short Mood and Feelings Questionnaire (sMFQ) is commonly used to measure depression symptoms in adolescence but has not been validated in young adulthood. This study aimed to (1) examine whether the sMFQ is valid in young adulthood, and (2) identify cut-points best capturing DSM-5 depression diagnosis at age 25 METHODS: The sample included participants in the Avon Longitudinal Study of Parents and Children (ALSPAC) at age 25 (n = 4098). Receiver Operating Characteristic analyses examined how well the self-rated sMFQ discriminates between cases and non-cases of DSM-5 Major Depressive Disorder (MDD) classified using the self-rated Development and Well Being Assessment. Sensitivity and specificity values were used to identify cut-points on the sMFQ RESULTS: The sMFQ had high accuracy for discriminating MDD cases from non-cases at age 25. The commonly used cut-point in adolescence (≥12) performed well at this age, best balancing sensitivity and specificity. However, a lower cut-point (≥10) may be appropriate when favouring sensitivity over specificity e.g., in context of screening. Sensitivity analyses suggested similar results for males and females LIMITATIONS: ALSPAC is a longitudinal population cohort that suffers from non-random attrition CONCLUSIONS: The sMFQ is a valid measure of depression in young adults in the general population. It can be used to screen for and monitor depression across adolescence and early adulthood.

Sections du résumé

BACKGROUND
Depression often onsets in adolescence and is associated with recurrence in adulthood. There is a need to identify and monitor depression symptoms across adolescence and into young adulthood. The short Mood and Feelings Questionnaire (sMFQ) is commonly used to measure depression symptoms in adolescence but has not been validated in young adulthood. This study aimed to (1) examine whether the sMFQ is valid in young adulthood, and (2) identify cut-points best capturing DSM-5 depression diagnosis at age 25 METHODS: The sample included participants in the Avon Longitudinal Study of Parents and Children (ALSPAC) at age 25 (n = 4098). Receiver Operating Characteristic analyses examined how well the self-rated sMFQ discriminates between cases and non-cases of DSM-5 Major Depressive Disorder (MDD) classified using the self-rated Development and Well Being Assessment. Sensitivity and specificity values were used to identify cut-points on the sMFQ RESULTS: The sMFQ had high accuracy for discriminating MDD cases from non-cases at age 25. The commonly used cut-point in adolescence (≥12) performed well at this age, best balancing sensitivity and specificity. However, a lower cut-point (≥10) may be appropriate when favouring sensitivity over specificity e.g., in context of screening. Sensitivity analyses suggested similar results for males and females LIMITATIONS: ALSPAC is a longitudinal population cohort that suffers from non-random attrition CONCLUSIONS: The sMFQ is a valid measure of depression in young adults in the general population. It can be used to screen for and monitor depression across adolescence and early adulthood.

Identifiants

pubmed: 34375216
pii: S0165-0327(21)00769-2
doi: 10.1016/j.jad.2021.07.090
pmc: PMC8411664
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

883-888

Subventions

Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : 217065/Z/19/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9815508
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204895/Z/16/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Références

Child Adolesc Psychiatry Ment Health. 2010 Feb 09;4(1):8
pubmed: 20181135
Psychiatry Res. 1998 Nov 16;81(2):259-68
pubmed: 9858042
Percept Mot Skills. 2007 Dec;105(3 Pt 1):997-1014
pubmed: 18229554
Lancet. 2012 Mar 17;379(9820):1056-67
pubmed: 22305766
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Autism Res. 2016 Dec;9(12):1353-1363
pubmed: 27120552
Mol Psychiatry. 2020 Aug;25(8):1631-1639
pubmed: 31959848
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
Genome Med. 2010 Sep 20;2(9):68
pubmed: 20860851
Soc Psychiatry Psychiatr Epidemiol. 2007 Apr;42(4):322-7
pubmed: 17334898
Br J Psychiatry. 2006 Mar;188:216-22
pubmed: 16507961
J Child Psychol Psychiatry. 2015 Mar;56(3):324-41
pubmed: 25496295
Int J Epidemiol. 2018 Aug 1;47(4):1207-1216
pubmed: 29800128
J Child Psychol Psychiatry. 1995 Feb;36(2):327-34
pubmed: 7759594
Psychol Assess. 2014 Sep;26(3):752-62
pubmed: 24749755
J Child Psychol Psychiatry. 2000 Jul;41(5):645-55
pubmed: 10946756
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Int J Methods Psychiatr Res. 2018 Sep;27(3):e1610
pubmed: 29465165
Br J Psychiatry. 1998 Jul;173:11-53
pubmed: 9850203
J Child Psychol Psychiatry. 2006 Sep;47(9):927-34
pubmed: 16930387
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
Wellcome Open Res. 2019 Mar 14;4:51
pubmed: 31020050
J Affect Disord. 2004 Feb;78(2):131-40
pubmed: 14706723
PLoS One. 2020 Mar 25;15(3):e0230623
pubmed: 32210463
Ann Clin Biochem. 1993 Nov;30 ( Pt 6):521-39
pubmed: 8304720

Auteurs

Olga Eyre (O)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom; Cwm Taf Morgannwg University Health Board Health Board, Wales, United Kingdom.

Rhys Bevan Jones (R)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom; Cwm Taf Morgannwg University Health Board Health Board, Wales, United Kingdom.

Sharifah Shameem Agha (SS)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom; Cwm Taf Morgannwg University Health Board Health Board, Wales, United Kingdom.

Robyn E Wootton (RE)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom; Nic Waals Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.

Ajay K Thapar (AK)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom.

Evie Stergiakouli (E)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom; Population Health Sciences, University of Bristol, Bristol, United Kingdom.

Kate Langley (K)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom; School of Psychology, Cardiff University, Wales, United Kingdom.

Stephan Collishaw (S)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom.

Anita Thapar (A)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom.

Lucy Riglin (L)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Wales, United Kingdom. Electronic address: riglinl@cardiff.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH